Vivek A Saraswat
Overview
Explore the profile of Vivek A Saraswat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choudhury A, Kulkarni A, Arora V, Soin A, Dokmeci A, Chowdhury A, et al.
Hepatol Int
. 2025 Feb;
19(1):1-69.
PMID: 39961976
Acute-on-chronic liver failure (ACLF) is a condition associated with high mortality in the absence of liver transplantation. There have been various definitions proposed worldwide. The first consensus report of the...
2.
Kumar A, Arora A, Choudhury A, Arora V, Rela M, Jothimani D, et al.
Am J Gastroenterol
. 2024 Jul;
PMID: 39016385
Introduction: The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) and its complication, MAFLD-related acute-on-chronic liver failure (MAFLD-ACLF), is rising. Yet, factors determining patient outcomes in MAFLD-ACLF remain understudied. Methods:...
3.
Kumar A, Acharya S, Singh S, Duseja A, Madan K, Shukla A, et al.
J Clin Exp Hepatol
. 2023 Dec;
14(1):101269.
PMID: 38107186
Hepatocellular carcinoma (HCC) presents significant treatment challenges despite considerable advancements in its management. The Indian National Association for the Study of the Liver (INASL) first published its guidelines to aid...
4.
Kulkarni A, Krishna V, Kumar K, Sharma M, Patodiya B, Khan A, et al.
J Clin Exp Hepatol
. 2023 Jul;
13(4):618-623.
PMID: 37440938
Background: Atezolizumab-bevacizumab (atezo/bev) combination is a recommended first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC). There are no studies from India reporting the safety and efficacy of this drug in...
5.
Arora A, Kumar A, Anand A, Kumar A, Yadav A, Bhagwat A, et al.
Indian J Gastroenterol
. 2023 Jun;
42(3):332-346.
PMID: 37273146
Antiplatelet and/or anticoagulant agents (collectively known as antithrombotic agents) are used to reduce the risk of thromboembolic events in patients with conditions such as atrial fibrillation, acute coronary syndrome, recurrent...
6.
Duseja A, Singh S, De A, Madan K, Rao P, Shukla A, et al.
J Clin Exp Hepatol
. 2023 Mar;
13(2):273-302.
PMID: 36950481
Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease globally and in India. The already high burden of NAFLD in India is expected to further increase...
7.
Ghany M, Saraswat V
Am J Gastroenterol
. 2023 Mar;
118(6):970-971.
PMID: 36940387
Patients with hepatitis B virus-related cirrhosis and low-level viremia represent a special group that might benefit from treatment because of their higher risk of complications. Evidence for the benefit of...
8.
Anand A, Nandi B, Acharya S, Arora A, Babu S, Batra Y, et al.
J Clin Exp Hepatol
. 2022 May;
12(2):729-730.
PMID: 35535113
[This corrects the article DOI: 10.1016/j.jceh.2020.04.011.].
9.
Saraswat V, Kumar K
J Clin Exp Hepatol
. 2022 May;
12(2):268-271.
PMID: 35535088
No abstract available.
10.
Kumar K, Kulkarni A, Mahala V, Saraswat V
Liver Int
. 2022 Mar;
42(5):1206.
PMID: 35294103
No abstract available.